Review



mog35 55 peptide mogp  (Biosynth Carbosynth)


Bioz Verified Symbol Biosynth Carbosynth is a verified supplier
Bioz Manufacturer Symbol Biosynth Carbosynth manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Biosynth Carbosynth mog35 55 peptide mogp
    Mog35 55 Peptide Mogp, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 92/100, based on 72 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pm28650992-82-23-26?v=Biosynth+Carbosynth
    Average 92 stars, based on 72 article reviews
    mog35 55 peptide mogp - by Bioz Stars, 2026-07
    92/100 stars

    Images



    Similar Products

    90
    EZBiolab Inc mog peptide (mogp) encompassing aa residues 35-55 of mog
    Mog Peptide (Mogp) Encompassing Aa Residues 35 55 Of Mog, supplied by EZBiolab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pmc05605454-95-8-21?v=EZBiolab+Inc
    Average 90 stars, based on 1 article reviews
    mog peptide (mogp) encompassing aa residues 35-55 of mog - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    EZBiolab Inc tetramer mog peptide (mogp)
    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg <t>MOGp</t> and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.
    Tetramer Mog Peptide (Mogp), supplied by EZBiolab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pmc05605454-42-3-25?v=EZBiolab+Inc
    Average 90 stars, based on 1 article reviews
    tetramer mog peptide (mogp) - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    EZBiolab Inc mog peptide (mogp)
    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg <t>MOGp</t> and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.
    Mog Peptide (Mogp), supplied by EZBiolab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pmc05605454-95-0-21?v=EZBiolab+Inc
    Average 90 stars, based on 1 article reviews
    mog peptide (mogp) - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    92
    Biosynth Carbosynth mog35 55 peptide mogp
    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg <t>MOGp</t> and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.
    Mog35 55 Peptide Mogp, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pm28650992-82-23-26?v=Biosynth+Carbosynth
    Average 92 stars, based on 1 article reviews
    mog35 55 peptide mogp - by Bioz Stars, 2026-07
    92/100 stars
      Buy from Supplier

    91
    Biosynth Carbosynth peptide mogp
    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg <t>MOGp</t> and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.
    Peptide Mogp, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pmc05484466-71-22-24?v=Biosynth+Carbosynth
    Average 91 stars, based on 1 article reviews
    peptide mogp - by Bioz Stars, 2026-07
    91/100 stars
      Buy from Supplier

    90
    CPC Scientific mog 35–55 peptide (mogp
    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg <t>MOGp</t> and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.
    Mog 35–55 Peptide (Mogp, supplied by CPC Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pmc03779698-52-27-31?v=CPC+Scientific
    Average 90 stars, based on 1 article reviews
    mog 35–55 peptide (mogp - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Biomatik mog 35–55 peptide (mogp)
    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg <t>MOGp</t> and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.
    Mog 35–55 Peptide (Mogp), supplied by Biomatik, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pmc03577977-145-16-20?v=Biomatik
    Average 90 stars, based on 1 article reviews
    mog 35–55 peptide (mogp) - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Biomatik mog 35–55 peptide mogp
    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg <t>MOGp</t> and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.
    Mog 35–55 Peptide Mogp, supplied by Biomatik, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pmc03577977-60-23-27?v=Biomatik
    Average 90 stars, based on 1 article reviews
    mog 35–55 peptide mogp - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Biotrend Chemicals mog peptide amino acids 35–55 mogp 35–55
    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg <t>MOGp</t> and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.
    Mog Peptide Amino Acids 35–55 Mogp 35–55, supplied by Biotrend Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/peptide+mogp/pmc01809476-44-11-18?v=Biotrend+Chemicals
    Average 90 stars, based on 1 article reviews
    mog peptide amino acids 35–55 mogp 35–55 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    Image Search Results


    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg MOGp and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg MOGp and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.

    Article Snippet: MOG peptide and tetramer MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Enzyme-linked Immunosorbent Assay, Two Tailed Test

    EAE was induced in 13R+/+ and 13R-/- C57BL/6 mice using 100 μg MOGp, the LN and CNS were harvested at the indicated days post-disease induction, and CD4+MOGtet+ T cells were analysed ex vivo for intracellular IFNγ and IL-17. (A) Shows the frequency of single as well as double cytokine producing CD4+MOGtet+ T cells in both the LN and the CNS. (B) Shows the absolute cell numbers accumulated in the CNS of CD4+MOGtet+ T cells producing IL-17 (left panel), IFNγ (median panel), or both (right panel). The data is compiled from 3 independent experiments. *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: EAE was induced in 13R+/+ and 13R-/- C57BL/6 mice using 100 μg MOGp, the LN and CNS were harvested at the indicated days post-disease induction, and CD4+MOGtet+ T cells were analysed ex vivo for intracellular IFNγ and IL-17. (A) Shows the frequency of single as well as double cytokine producing CD4+MOGtet+ T cells in both the LN and the CNS. (B) Shows the absolute cell numbers accumulated in the CNS of CD4+MOGtet+ T cells producing IL-17 (left panel), IFNγ (median panel), or both (right panel). The data is compiled from 3 independent experiments. *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test.

    Article Snippet: MOG peptide and tetramer MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Ex Vivo, Two Tailed Test

    (A, B) 13R+/+ and 13R-/- IL-17acre-eYFP mice were induced for EAE with 100 μg MOGp, the LN were harvested on day 7 post-disease induction and the frequency of YFP expressing CD4+IL-17+ (A) and CD4+IFNγ+ (B) T cells was determined by flow cytometry. (C-H) LN and CNS cells were harvested on days 4, 5 and 6 (C, D) or every 6 hours beginning on day 4 as indicated (E-H) and expression of Tbet and RoRγt by CD4+MOGtet+YFP+ cells was measured ex vivo by intracellular staining. (C, D) Show the frequency of CD4+MOGtet+YFP+ cells expressing Tbet and/or RoRγt in the LN (C) and CNS (D). (E-H) show the mean ± SD of the absolute numbers of CD4+MOGtet+YFP+ double positive for RoRγt and Tbet in (E, F) or Tbet single positive (G, H). Data is compiled from 3 independent experiments. *, p<0.05; **, p<0.01 as determined by two-tailed, unpaired Student's t-test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: (A, B) 13R+/+ and 13R-/- IL-17acre-eYFP mice were induced for EAE with 100 μg MOGp, the LN were harvested on day 7 post-disease induction and the frequency of YFP expressing CD4+IL-17+ (A) and CD4+IFNγ+ (B) T cells was determined by flow cytometry. (C-H) LN and CNS cells were harvested on days 4, 5 and 6 (C, D) or every 6 hours beginning on day 4 as indicated (E-H) and expression of Tbet and RoRγt by CD4+MOGtet+YFP+ cells was measured ex vivo by intracellular staining. (C, D) Show the frequency of CD4+MOGtet+YFP+ cells expressing Tbet and/or RoRγt in the LN (C) and CNS (D). (E-H) show the mean ± SD of the absolute numbers of CD4+MOGtet+YFP+ double positive for RoRγt and Tbet in (E, F) or Tbet single positive (G, H). Data is compiled from 3 independent experiments. *, p<0.05; **, p<0.01 as determined by two-tailed, unpaired Student's t-test.

    Article Snippet: MOG peptide and tetramer MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Expressing, Flow Cytometry, Ex Vivo, Staining, Two Tailed Test

    Thy (A), SP (B), and LN (C) were harvested from naïve 13R+/+ and 13R-/- mice and the frequency of CD4+Foxp3+ Treg was determined by flow cytometry. (D, E) 13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization the SP cells were used to isolate effector Th1 and Th17 cells whereas the LN cells were utilized to sort CD4+CD25+Foxp3+(GFP+) Tregs. Effector Th1 and Th17 cells from 13R+/+ (D) and 13R-/- (E) mice were then co-cultured with the LN Tregs from both strains and suppression of effector function was evaluated by measuring residual IFNγ and IL-17 production by ELISA. The percent of residual cytokine represent the ratio of cytokine obtained in the presence of Tregs over cytokine produced in the absence of Tregs multiplied by 100. Data is representative of at least 3 independent experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: Thy (A), SP (B), and LN (C) were harvested from naïve 13R+/+ and 13R-/- mice and the frequency of CD4+Foxp3+ Treg was determined by flow cytometry. (D, E) 13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization the SP cells were used to isolate effector Th1 and Th17 cells whereas the LN cells were utilized to sort CD4+CD25+Foxp3+(GFP+) Tregs. Effector Th1 and Th17 cells from 13R+/+ (D) and 13R-/- (E) mice were then co-cultured with the LN Tregs from both strains and suppression of effector function was evaluated by measuring residual IFNγ and IL-17 production by ELISA. The percent of residual cytokine represent the ratio of cytokine obtained in the presence of Tregs over cytokine produced in the absence of Tregs multiplied by 100. Data is representative of at least 3 independent experiments.

    Article Snippet: MOG peptide and tetramer MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Flow Cytometry, Cell Culture, Enzyme-linked Immunosorbent Assay, Produced

    13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization splenic effector Th1 cells from both strains were re-stimulated with PMA and ionomycin, isolated based on cytokine secretion and co-cultured with Tregs from the LN of 13R+/+ or 13R-/- mice. (A) Shows IFNγ production in cultures where the Th1 cells from either strain were co-cultured with Tregs from 13R+/+ mice at Treg/Th1 ratios of 1:1 and 1:4. (B) Shows the percent residual IFNγ production obtained at the indicated Treg:Th1 ratios (see Materials and Methods). The dashed lines indicate the inhibition ratios 50 (IR50), which is the Treg to T effector ratio at which the residual cytokine production is reduced by 50% (see Material and Methods). *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test. (C) Shows the IR50± SD for Th1 effectors obtained with Tregs from 13R+/+ and 13R-/- mice. The SI (sensitivity index) represents the absolute amount of IFNγ that an effector Th1 cell could not produce due to suppression by Tregs (see Material and Methods). Data is compiled from 3 independent experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization splenic effector Th1 cells from both strains were re-stimulated with PMA and ionomycin, isolated based on cytokine secretion and co-cultured with Tregs from the LN of 13R+/+ or 13R-/- mice. (A) Shows IFNγ production in cultures where the Th1 cells from either strain were co-cultured with Tregs from 13R+/+ mice at Treg/Th1 ratios of 1:1 and 1:4. (B) Shows the percent residual IFNγ production obtained at the indicated Treg:Th1 ratios (see Materials and Methods). The dashed lines indicate the inhibition ratios 50 (IR50), which is the Treg to T effector ratio at which the residual cytokine production is reduced by 50% (see Material and Methods). *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test. (C) Shows the IR50± SD for Th1 effectors obtained with Tregs from 13R+/+ and 13R-/- mice. The SI (sensitivity index) represents the absolute amount of IFNγ that an effector Th1 cell could not produce due to suppression by Tregs (see Material and Methods). Data is compiled from 3 independent experiments.

    Article Snippet: MOG peptide and tetramer MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Isolation, Cell Culture, Inhibition, Two Tailed Test

    13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization splenic effector Th17 cells from both strains were re-stimulated with PMA and ionomycin, isolated based on cytokine secretion and co-cultured with Tregs from the LN of 13R+/+ or 13R-/- mice. (A) Shows IL-17 production in cultures where the Th17 cells from either strain were co-cultured with Tregs from 13R+/+ mice at Treg/Th17 ratios of 1:1 and 1:4. (B) Shows the percent residual IL-17 production obtained at the indicated Treg:Th17 ratios. The dashed lines indicate the IR50 at which the residual cytokine production is reduced by 50%. *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test. (C) Shows the IR50± SD for Th17 effectors obtained with Tregs from 13R+/+ and 13R-/- mice. The SI represents the absolute amount of IL-17 that an effector Th17 cell could not produce due to suppression by Tregs. Data is compiled from 3 independent experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization splenic effector Th17 cells from both strains were re-stimulated with PMA and ionomycin, isolated based on cytokine secretion and co-cultured with Tregs from the LN of 13R+/+ or 13R-/- mice. (A) Shows IL-17 production in cultures where the Th17 cells from either strain were co-cultured with Tregs from 13R+/+ mice at Treg/Th17 ratios of 1:1 and 1:4. (B) Shows the percent residual IL-17 production obtained at the indicated Treg:Th17 ratios. The dashed lines indicate the IR50 at which the residual cytokine production is reduced by 50%. *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test. (C) Shows the IR50± SD for Th17 effectors obtained with Tregs from 13R+/+ and 13R-/- mice. The SI represents the absolute amount of IL-17 that an effector Th17 cell could not produce due to suppression by Tregs. Data is compiled from 3 independent experiments.

    Article Snippet: MOG peptide and tetramer MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Isolation, Cell Culture, Two Tailed Test

    13R+/+ Foxp3-GFP and 13R-/- mice were immunized with 100μg MOGp s.c. in PBS/CFA and 10 days later the SP were used to isolate effector Th1 cells. Also, the LN from 13R+/+ Foxp3-GFP mice were utilized to sort CD4+CD25+GFP+(Foxp3+) Tregs to serve for suppression. The Th1 cells were then transferred (1 ×106 Th1 cells per mouse) i.v. into Rag2-/- C57BL/6 mice (6 mice per group) with or without Tregs (2.5 ×106 cells per mouse). On day 2 after transfer the hosts were induced for EAE with 100μg MOGp. (A) Shows the mean clinical scores ± SD for hosts recipient of Th1 effector cells from 13R+/+ mice without (13R+/+ + Nil) or with (13R+/+ + Tregs) Tregs. (B) Shows the mean clinical scores ± SD for hosts recipient of Th1 effector cells from 13R-/- mice without (13R-/- + Nil) or with (13R-/- + Tregs) Tregs. (C) Shows comparison of the mean clinical scores ± SD of hosts recipient of Tregs and Th1 effector cells from 13R+/+ versus 13R-/- mice. **p<0.01 as determined by Mann-Whitney U test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R+/+ Foxp3-GFP and 13R-/- mice were immunized with 100μg MOGp s.c. in PBS/CFA and 10 days later the SP were used to isolate effector Th1 cells. Also, the LN from 13R+/+ Foxp3-GFP mice were utilized to sort CD4+CD25+GFP+(Foxp3+) Tregs to serve for suppression. The Th1 cells were then transferred (1 ×106 Th1 cells per mouse) i.v. into Rag2-/- C57BL/6 mice (6 mice per group) with or without Tregs (2.5 ×106 cells per mouse). On day 2 after transfer the hosts were induced for EAE with 100μg MOGp. (A) Shows the mean clinical scores ± SD for hosts recipient of Th1 effector cells from 13R+/+ mice without (13R+/+ + Nil) or with (13R+/+ + Tregs) Tregs. (B) Shows the mean clinical scores ± SD for hosts recipient of Th1 effector cells from 13R-/- mice without (13R-/- + Nil) or with (13R-/- + Tregs) Tregs. (C) Shows comparison of the mean clinical scores ± SD of hosts recipient of Tregs and Th1 effector cells from 13R+/+ versus 13R-/- mice. **p<0.01 as determined by Mann-Whitney U test.

    Article Snippet: MOG peptide and tetramer MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Comparison, MANN-WHITNEY

    13R+/+ Foxp3-GFP and 13R-/- mice were immunized with 100μg MOGp s.c. in PBS/CFA and 10 days later the SP were used to isolate effector Th17 cells. Also, the LN from 13R+/+ Foxp3-GFP mice were utilized to sort CD4+CD25+GFP+(Foxp3+) Tregs to serve for suppression. The Th17 cells were then transferred (4 ×106 Th17 cells per mouse) i.v. into Rag2-/- C57BL/6 mice (6 mice per group) with or without Tregs (2 ×106 cells per mouse). On day 2 after transfer the hosts were induced for EAE with 100μg MOGp. (A) Shows the mean clinical scores ± SD for hosts recipient of Th17 effector cells from 13R+/+ mice without (13R+/+ + Nil) or with (13R+/+ + Tregs) Tregs. (B) Shows the mean clinical scores ± SD for hosts recipient of Th17 effector cells from 13R-/- mice without (13R-/- + Nil) or with (13R-/- + Tregs) Tregs. (C) Shows comparison of the mean clinical scores ± SD of hosts recipient of Tregs and Th17 effector cells from 13R+/+ versus 13R-/- mice. **p<0.01 and ***p<0.001 as determined by Mann-Whitney U test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R+/+ Foxp3-GFP and 13R-/- mice were immunized with 100μg MOGp s.c. in PBS/CFA and 10 days later the SP were used to isolate effector Th17 cells. Also, the LN from 13R+/+ Foxp3-GFP mice were utilized to sort CD4+CD25+GFP+(Foxp3+) Tregs to serve for suppression. The Th17 cells were then transferred (4 ×106 Th17 cells per mouse) i.v. into Rag2-/- C57BL/6 mice (6 mice per group) with or without Tregs (2 ×106 cells per mouse). On day 2 after transfer the hosts were induced for EAE with 100μg MOGp. (A) Shows the mean clinical scores ± SD for hosts recipient of Th17 effector cells from 13R+/+ mice without (13R+/+ + Nil) or with (13R+/+ + Tregs) Tregs. (B) Shows the mean clinical scores ± SD for hosts recipient of Th17 effector cells from 13R-/- mice without (13R-/- + Nil) or with (13R-/- + Tregs) Tregs. (C) Shows comparison of the mean clinical scores ± SD of hosts recipient of Tregs and Th17 effector cells from 13R+/+ versus 13R-/- mice. **p<0.01 and ***p<0.001 as determined by Mann-Whitney U test.

    Article Snippet: MOG peptide and tetramer MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Comparison, MANN-WHITNEY

    13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg MOGp and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R-/- mice develop early onset and more severe EAE. 13R+/+ and 13R-/- C57BL/6 mice (6-8 per group) were induced for EAE with 300μg MOGp and monitored daily for clinical signs of paralysis. (A, B) Mean clinical score of disease severity ± SD and percentage of mice that remained disease free for the initial 10 day-phase of disease onset. (C) Shows the mean clinical score of disease severity ± SD for the entire 30 day-monitoing phase. (D-F) Show mean clinical score of disease severity ± SD for 13R+/+ and 13R-/- mice (6 mice per group) induced for EAE with 100 (D), 60, (E) or 20 (F) μg of MOGp. *p<0.05, **p<0.01 as determined by Mann-Whitneys U test. (G-I) Draining lymph nodes were harvested at day 10 post-disease induction from mice induced for EAE with 100μg MOGp and the cells were stimulated with PMA and ionomycin (G, H,) or graded concentrations of MOGp (I) and IFNγ and IL-17 responses were measured. (G) Shows the percentages while (H) illustrates the absolute numbers of cytokine secreting CD4+MOGtet+ T cells. (I) Shows cytokine secretion as measured by ELISA. Data is representative of at least 3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed, unpaired Student's t-test.

    Article Snippet: MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Enzyme-linked Immunosorbent Assay, Two Tailed Test

    EAE was induced in 13R+/+ and 13R-/- C57BL/6 mice using 100 μg MOGp, the LN and CNS were harvested at the indicated days post-disease induction, and CD4+MOGtet+ T cells were analysed ex vivo for intracellular IFNγ and IL-17. (A) Shows the frequency of single as well as double cytokine producing CD4+MOGtet+ T cells in both the LN and the CNS. (B) Shows the absolute cell numbers accumulated in the CNS of CD4+MOGtet+ T cells producing IL-17 (left panel), IFNγ (median panel), or both (right panel). The data is compiled from 3 independent experiments. *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: EAE was induced in 13R+/+ and 13R-/- C57BL/6 mice using 100 μg MOGp, the LN and CNS were harvested at the indicated days post-disease induction, and CD4+MOGtet+ T cells were analysed ex vivo for intracellular IFNγ and IL-17. (A) Shows the frequency of single as well as double cytokine producing CD4+MOGtet+ T cells in both the LN and the CNS. (B) Shows the absolute cell numbers accumulated in the CNS of CD4+MOGtet+ T cells producing IL-17 (left panel), IFNγ (median panel), or both (right panel). The data is compiled from 3 independent experiments. *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test.

    Article Snippet: MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Ex Vivo, Two Tailed Test

    (A, B) 13R+/+ and 13R-/- IL-17acre-eYFP mice were induced for EAE with 100 μg MOGp, the LN were harvested on day 7 post-disease induction and the frequency of YFP expressing CD4+IL-17+ (A) and CD4+IFNγ+ (B) T cells was determined by flow cytometry. (C-H) LN and CNS cells were harvested on days 4, 5 and 6 (C, D) or every 6 hours beginning on day 4 as indicated (E-H) and expression of Tbet and RoRγt by CD4+MOGtet+YFP+ cells was measured ex vivo by intracellular staining. (C, D) Show the frequency of CD4+MOGtet+YFP+ cells expressing Tbet and/or RoRγt in the LN (C) and CNS (D). (E-H) show the mean ± SD of the absolute numbers of CD4+MOGtet+YFP+ double positive for RoRγt and Tbet in (E, F) or Tbet single positive (G, H). Data is compiled from 3 independent experiments. *, p<0.05; **, p<0.01 as determined by two-tailed, unpaired Student's t-test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: (A, B) 13R+/+ and 13R-/- IL-17acre-eYFP mice were induced for EAE with 100 μg MOGp, the LN were harvested on day 7 post-disease induction and the frequency of YFP expressing CD4+IL-17+ (A) and CD4+IFNγ+ (B) T cells was determined by flow cytometry. (C-H) LN and CNS cells were harvested on days 4, 5 and 6 (C, D) or every 6 hours beginning on day 4 as indicated (E-H) and expression of Tbet and RoRγt by CD4+MOGtet+YFP+ cells was measured ex vivo by intracellular staining. (C, D) Show the frequency of CD4+MOGtet+YFP+ cells expressing Tbet and/or RoRγt in the LN (C) and CNS (D). (E-H) show the mean ± SD of the absolute numbers of CD4+MOGtet+YFP+ double positive for RoRγt and Tbet in (E, F) or Tbet single positive (G, H). Data is compiled from 3 independent experiments. *, p<0.05; **, p<0.01 as determined by two-tailed, unpaired Student's t-test.

    Article Snippet: MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Expressing, Flow Cytometry, Ex Vivo, Staining, Two Tailed Test

    Thy (A), SP (B), and LN (C) were harvested from naïve 13R+/+ and 13R-/- mice and the frequency of CD4+Foxp3+ Treg was determined by flow cytometry. (D, E) 13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization the SP cells were used to isolate effector Th1 and Th17 cells whereas the LN cells were utilized to sort CD4+CD25+Foxp3+(GFP+) Tregs. Effector Th1 and Th17 cells from 13R+/+ (D) and 13R-/- (E) mice were then co-cultured with the LN Tregs from both strains and suppression of effector function was evaluated by measuring residual IFNγ and IL-17 production by ELISA. The percent of residual cytokine represent the ratio of cytokine obtained in the presence of Tregs over cytokine produced in the absence of Tregs multiplied by 100. Data is representative of at least 3 independent experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: Thy (A), SP (B), and LN (C) were harvested from naïve 13R+/+ and 13R-/- mice and the frequency of CD4+Foxp3+ Treg was determined by flow cytometry. (D, E) 13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization the SP cells were used to isolate effector Th1 and Th17 cells whereas the LN cells were utilized to sort CD4+CD25+Foxp3+(GFP+) Tregs. Effector Th1 and Th17 cells from 13R+/+ (D) and 13R-/- (E) mice were then co-cultured with the LN Tregs from both strains and suppression of effector function was evaluated by measuring residual IFNγ and IL-17 production by ELISA. The percent of residual cytokine represent the ratio of cytokine obtained in the presence of Tregs over cytokine produced in the absence of Tregs multiplied by 100. Data is representative of at least 3 independent experiments.

    Article Snippet: MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Flow Cytometry, Cell Culture, Enzyme-linked Immunosorbent Assay, Produced

    13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization splenic effector Th1 cells from both strains were re-stimulated with PMA and ionomycin, isolated based on cytokine secretion and co-cultured with Tregs from the LN of 13R+/+ or 13R-/- mice. (A) Shows IFNγ production in cultures where the Th1 cells from either strain were co-cultured with Tregs from 13R+/+ mice at Treg/Th1 ratios of 1:1 and 1:4. (B) Shows the percent residual IFNγ production obtained at the indicated Treg:Th1 ratios (see Materials and Methods). The dashed lines indicate the inhibition ratios 50 (IR50), which is the Treg to T effector ratio at which the residual cytokine production is reduced by 50% (see Material and Methods). *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test. (C) Shows the IR50± SD for Th1 effectors obtained with Tregs from 13R+/+ and 13R-/- mice. The SI (sensitivity index) represents the absolute amount of IFNγ that an effector Th1 cell could not produce due to suppression by Tregs (see Material and Methods). Data is compiled from 3 independent experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization splenic effector Th1 cells from both strains were re-stimulated with PMA and ionomycin, isolated based on cytokine secretion and co-cultured with Tregs from the LN of 13R+/+ or 13R-/- mice. (A) Shows IFNγ production in cultures where the Th1 cells from either strain were co-cultured with Tregs from 13R+/+ mice at Treg/Th1 ratios of 1:1 and 1:4. (B) Shows the percent residual IFNγ production obtained at the indicated Treg:Th1 ratios (see Materials and Methods). The dashed lines indicate the inhibition ratios 50 (IR50), which is the Treg to T effector ratio at which the residual cytokine production is reduced by 50% (see Material and Methods). *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test. (C) Shows the IR50± SD for Th1 effectors obtained with Tregs from 13R+/+ and 13R-/- mice. The SI (sensitivity index) represents the absolute amount of IFNγ that an effector Th1 cell could not produce due to suppression by Tregs (see Material and Methods). Data is compiled from 3 independent experiments.

    Article Snippet: MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Isolation, Cell Culture, Inhibition, Two Tailed Test

    13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization splenic effector Th17 cells from both strains were re-stimulated with PMA and ionomycin, isolated based on cytokine secretion and co-cultured with Tregs from the LN of 13R+/+ or 13R-/- mice. (A) Shows IL-17 production in cultures where the Th17 cells from either strain were co-cultured with Tregs from 13R+/+ mice at Treg/Th17 ratios of 1:1 and 1:4. (B) Shows the percent residual IL-17 production obtained at the indicated Treg:Th17 ratios. The dashed lines indicate the IR50 at which the residual cytokine production is reduced by 50%. *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test. (C) Shows the IR50± SD for Th17 effectors obtained with Tregs from 13R+/+ and 13R-/- mice. The SI represents the absolute amount of IL-17 that an effector Th17 cell could not produce due to suppression by Tregs. Data is compiled from 3 independent experiments.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R+/+ and 13R-/- Foxp3-GFP mice were immunized with 100 μg MOGp s.c. in PBS/CFA and on day 10 post-immunization splenic effector Th17 cells from both strains were re-stimulated with PMA and ionomycin, isolated based on cytokine secretion and co-cultured with Tregs from the LN of 13R+/+ or 13R-/- mice. (A) Shows IL-17 production in cultures where the Th17 cells from either strain were co-cultured with Tregs from 13R+/+ mice at Treg/Th17 ratios of 1:1 and 1:4. (B) Shows the percent residual IL-17 production obtained at the indicated Treg:Th17 ratios. The dashed lines indicate the IR50 at which the residual cytokine production is reduced by 50%. *p<0.05, **p<0.01 as determined by two-tailed, unpaired Student's t-test. (C) Shows the IR50± SD for Th17 effectors obtained with Tregs from 13R+/+ and 13R-/- mice. The SI represents the absolute amount of IL-17 that an effector Th17 cell could not produce due to suppression by Tregs. Data is compiled from 3 independent experiments.

    Article Snippet: MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Isolation, Cell Culture, Two Tailed Test

    13R+/+ Foxp3-GFP and 13R-/- mice were immunized with 100μg MOGp s.c. in PBS/CFA and 10 days later the SP were used to isolate effector Th1 cells. Also, the LN from 13R+/+ Foxp3-GFP mice were utilized to sort CD4+CD25+GFP+(Foxp3+) Tregs to serve for suppression. The Th1 cells were then transferred (1 ×106 Th1 cells per mouse) i.v. into Rag2-/- C57BL/6 mice (6 mice per group) with or without Tregs (2.5 ×106 cells per mouse). On day 2 after transfer the hosts were induced for EAE with 100μg MOGp. (A) Shows the mean clinical scores ± SD for hosts recipient of Th1 effector cells from 13R+/+ mice without (13R+/+ + Nil) or with (13R+/+ + Tregs) Tregs. (B) Shows the mean clinical scores ± SD for hosts recipient of Th1 effector cells from 13R-/- mice without (13R-/- + Nil) or with (13R-/- + Tregs) Tregs. (C) Shows comparison of the mean clinical scores ± SD of hosts recipient of Tregs and Th1 effector cells from 13R+/+ versus 13R-/- mice. **p<0.01 as determined by Mann-Whitney U test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R+/+ Foxp3-GFP and 13R-/- mice were immunized with 100μg MOGp s.c. in PBS/CFA and 10 days later the SP were used to isolate effector Th1 cells. Also, the LN from 13R+/+ Foxp3-GFP mice were utilized to sort CD4+CD25+GFP+(Foxp3+) Tregs to serve for suppression. The Th1 cells were then transferred (1 ×106 Th1 cells per mouse) i.v. into Rag2-/- C57BL/6 mice (6 mice per group) with or without Tregs (2.5 ×106 cells per mouse). On day 2 after transfer the hosts were induced for EAE with 100μg MOGp. (A) Shows the mean clinical scores ± SD for hosts recipient of Th1 effector cells from 13R+/+ mice without (13R+/+ + Nil) or with (13R+/+ + Tregs) Tregs. (B) Shows the mean clinical scores ± SD for hosts recipient of Th1 effector cells from 13R-/- mice without (13R-/- + Nil) or with (13R-/- + Tregs) Tregs. (C) Shows comparison of the mean clinical scores ± SD of hosts recipient of Tregs and Th1 effector cells from 13R+/+ versus 13R-/- mice. **p<0.01 as determined by Mann-Whitney U test.

    Article Snippet: MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Comparison, MANN-WHITNEY

    13R+/+ Foxp3-GFP and 13R-/- mice were immunized with 100μg MOGp s.c. in PBS/CFA and 10 days later the SP were used to isolate effector Th17 cells. Also, the LN from 13R+/+ Foxp3-GFP mice were utilized to sort CD4+CD25+GFP+(Foxp3+) Tregs to serve for suppression. The Th17 cells were then transferred (4 ×106 Th17 cells per mouse) i.v. into Rag2-/- C57BL/6 mice (6 mice per group) with or without Tregs (2 ×106 cells per mouse). On day 2 after transfer the hosts were induced for EAE with 100μg MOGp. (A) Shows the mean clinical scores ± SD for hosts recipient of Th17 effector cells from 13R+/+ mice without (13R+/+ + Nil) or with (13R+/+ + Tregs) Tregs. (B) Shows the mean clinical scores ± SD for hosts recipient of Th17 effector cells from 13R-/- mice without (13R-/- + Nil) or with (13R-/- + Tregs) Tregs. (C) Shows comparison of the mean clinical scores ± SD of hosts recipient of Tregs and Th17 effector cells from 13R+/+ versus 13R-/- mice. **p<0.01 and ***p<0.001 as determined by Mann-Whitney U test.

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    Article Title: IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Treg Suppression to Restrain Experimental Allergic Encephalomyelitis

    doi: 10.4049/jimmunol.1700372

    Figure Lengend Snippet: 13R+/+ Foxp3-GFP and 13R-/- mice were immunized with 100μg MOGp s.c. in PBS/CFA and 10 days later the SP were used to isolate effector Th17 cells. Also, the LN from 13R+/+ Foxp3-GFP mice were utilized to sort CD4+CD25+GFP+(Foxp3+) Tregs to serve for suppression. The Th17 cells were then transferred (4 ×106 Th17 cells per mouse) i.v. into Rag2-/- C57BL/6 mice (6 mice per group) with or without Tregs (2 ×106 cells per mouse). On day 2 after transfer the hosts were induced for EAE with 100μg MOGp. (A) Shows the mean clinical scores ± SD for hosts recipient of Th17 effector cells from 13R+/+ mice without (13R+/+ + Nil) or with (13R+/+ + Tregs) Tregs. (B) Shows the mean clinical scores ± SD for hosts recipient of Th17 effector cells from 13R-/- mice without (13R-/- + Nil) or with (13R-/- + Tregs) Tregs. (C) Shows comparison of the mean clinical scores ± SD of hosts recipient of Tregs and Th17 effector cells from 13R+/+ versus 13R-/- mice. **p<0.01 and ***p<0.001 as determined by Mann-Whitney U test.

    Article Snippet: MOG peptide (MOGp) encompassing aa residues 35-55 of MOG which is encephalitogenic in C57BL/6 mice ( 23 ) was purchased from EZBiolab (Westfield, IN).

    Techniques: Comparison, MANN-WHITNEY